NPB-01-ME

Phase 3Small molecule

NNihon Pharmaceutical Co., Ltd

NPB-01-ME is one of 18 small molecule programs targeting Autoimmune Encephalitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune EncephalitisActive, not recruiting

Autoimmune EncephalitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Autoimmune Encephalitis

#DrugCompanyPhaseTrials

Medrol

PROCRIT

1 3

ENSPRYNG

Roche

Phase 3

1 4

Kesimpta

Novartis

Phase 3

1 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Rysodeg

1 7

Ocrevus

Roche

Phase 2

1 8

NPB-01

NNihon Pharmaceutical Co., Ltd

Phase 3

1 9

Minocin

TTriax

Phase 2

1 10

Velcade

SShilpa Grover, MD, MPH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmune Encephalitis1 trial

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Unknown status·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT05177939·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NPB-01-ME. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NPB-01-ME compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NPB-01-ME. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nihon Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNihon Pharmaceutical Co., Ltd

NPB-01-ME

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmune Encephalitis1 trial

References

Drug Info

Quick Facts

Related News